Compare CHH & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHH | BLCO |
|---|---|---|
| Founded | 1939 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Ophthalmic Goods |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 5.4B |
| IPO Year | 1997 | 2022 |
| Metric | CHH | BLCO |
|---|---|---|
| Price | $115.01 | $14.93 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 11 |
| Target Price | ★ $114.30 | $18.45 |
| AVG Volume (30 Days) | ★ 626.2K | 408.0K |
| Earning Date | 04-30-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.98% | N/A |
| EPS Growth | ★ 27.42 | N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | $1,596,793,000.00 | ★ $5,101,000,000.00 |
| Revenue This Year | $66.74 | $8.65 |
| Revenue Next Year | $0.37 | $5.59 |
| P/E Ratio | $261.02 | ★ N/A |
| Revenue Growth | 0.75 | ★ 6.47 |
| 52 Week Low | $84.04 | $11.63 |
| 52 Week High | $136.45 | $18.92 |
| Indicator | CHH | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 57.25 | 37.00 |
| Support Level | $102.06 | $14.61 |
| Resistance Level | $116.89 | $15.67 |
| Average True Range (ATR) | 4.30 | 0.39 |
| MACD | 0.70 | -0.03 |
| Stochastic Oscillator | 80.87 | 19.73 |
At year-end 2025, Choice Hotels operated 657,000 rooms across the economy, midscale, upscale, and extended-stay segments. Comfort Inn and Comfort Suites are the largest brands (27% of the company's total rooms), while Ascend and Cambria (10%) are lifestyle and select-service brands, and WoodSpring (5%) is the company's largest extended-stay brand. Choice closed on its Radisson acquisition in August 2022, which added about 70,000 rooms. Franchises account for 100% of total revenue, and the United States represented 78% of total rooms in 2025.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.